Nektar Therapeutics | NKTR - Interest Expense On Debt


Nektar Therapeutics reported $6.02M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 12.28M 7.63M Dec/2025
Amgen USD 653M 32M Dec/2025
Baxter International USD 58M 14M Sep/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cara Therapeutics 43.75M 4.8M Jun/2025
Cipla INR 140.3M 8.5M Dec/2025
Dr.Reddys Laboratories INR 944M 37M Dec/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Xencor USD 7.35M 311K Dec/2025